Passage 1 (P1) Mesenchymal Stem Cells (MSCs), known as "Golden Cells", are the most powerful and clinically effective stem cells available.
Stem cells, like all living organisms, follow a natural lifecycle: they are born, mature when they are most powerful, and decline with age. Among the many types of adult stem cells, those derived from healthy birth umbilical cords have the most clinical evidence supporting their efficacy and safety.
For doctors, the challenge lies in selecting the most effective cells for optimal patient outcomes. The answer lies in Passage One (P1) Mesenchymal Stem Cells (MSCs), often referred to as "Golden Cells."
Advances in science now allow stem cells to be "selected" for their ability to repair tissues. This selection process removes cells that are too young, too old, or not in optimal condition, leaving only the most potent cells for treatment—these are the "Golden Cells."
"Golden Cells" need to be multiplied to produce sufficient quantities for effective treatment. During this process, cells grow until they reach "overcrowding," at which point they are transferred to a new plate—this transfer is called a "Passage." Passage 1 cells have only undergone one passage, maintaining their strength and vitality. In contrast, cells grown over many passages become weaker and lose their potency.
When mesenchymal stem cells are harvested from the umbilical cord, there are two methods to isolate immune-privileged cells. The quicker, less expensive method involves using harsh chemicals, which can damage the cells. The optimal approach, however, is micro-dissection—a manual, gentle process that coaxes the cells onto a culture plate. This careful method is crucial for preserving the cells' integrity, as the chemical method risks epigenetic damage, while micro-dissection ensures the cells remain more effective for clinical use
Once mesenchymal stem cells (MSCs) are isolated from the umbilical cord, they must be expanded. As MSCs expand in culture, they begin to lose their secretome—the secretions, including exosomes, that allow them to communicate with other cells and promote repair. Passage 1 (P1) cells are only cultured until the dish is 80% full, then split into new dishes. When those dishes reach 80% confluence, the cells are flash-frozen, preserving them in their most potent and clinically effective state, as supported by peer-reviewed research.
Culturing cells beyond P1, into passages 3, 4, or higher, causes them to become unstable, larger, and less capable of communication. These later-passage cells result in poor clinical outcomes and reduced patient satisfaction. P1 cells, on the other hand, provide doctors with more consistent results and a higher predictability of treatment success in regenerative medicine.
After a decade of clinical experience, advancements now allow us to "prime" or "instruct" Passage 1 (P1) mesenchymal stem cells to better align with the physician's clinical objectives. By gently exposing these cells to specific peptides and natural compounds, we can sensitize and prepare them for the intended repair task. These substances are added before clinical application, effectively guiding the cells toward the types of tissues they will likely help regenerate.
Orthopedic injections
Neurological regeneration
Skin and collagen regeneration
Liver conditions
Gastrointestinal
Anti-aging
Autoimmune dysfunction
Often referred to as the “Holy Grail” of stem cells, iPSC technology offers patients the opportunity to create and bank their own personalized cell line using their own DNA for future clinical applications. Building on the groundbreaking work of Dr. Shinya Yamanaka, who won the Nobel Prize for Medicine in 2012, it is now possible to reprogram a skin cell into an embryonic-like stem cell, or iPSC—the most potent type of stem cell available.
Having one’s own cell lines available in the case of future medical requirements is the highest level of bio-insurance anyone can have. iPSCs – The future of stem cells is available now.
iPSCs are derived from skin cells that have been reprogrammed into an embryonic-like pluripotent state, enabling the development of any human cell type needed for therapeutic purposes or cellular research. These cells are capable of unlimited self-renewal and differentiation into any cell type within the human body.
Cell Source for Therapeutic Applications: iPSCs can be differentiated into various cell types for targeted therapies.
Disease Modeling: iPSCs are used for creating 3D organoids and studying phenotypes, gene expression, molecular secretions, and drug interactions.
Gene-Corrected Cell Banking: iPSCs offer the possibility of storing genetically corrected cells for future use.
Our laboratory is a full-scale culture and analysis facility specializing in iPSCs. We have developed a non-integrating mRNA method to induce pluripotency in adult stromal cells. Our protocols for expansion, characterization, and cryogenic storage are performed to international standards.
Adult stem cells have been safely used for over 60 years, initially in bone marrow transplants. Over the past 15 years, the use of mesenchymal stem cells (MSCs) has expanded, with more than 300,000 patients treated in peer-reviewed clinical trials, demonstrating both safety and efficacy worldwide.
Orthopedic – Treating knees, hips, and shoulders.
Facial Rejuvenation – Supporting skin repair and revitalization.
Anti-Aging – Whole-body treatments for vitality and regeneration.
Back Pain – Regenerating lower back muscles.
Neck & Shoulder – Addressing office-related musculoskeletal issues.
At ReGenMed we pride ourselves on our ability to support medical professionals and enhance patient outcomes. Get in touch with a member of our team today to find out more.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Results may vary, and individual outcomes are not guaranteed.
Your trusted biomedicine provider since 2007.
Copyright @ Regenerative Medicine Co, Ltd. All Rights Reserved